The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Status:
RECRUITING
Trial end date:
2027-07-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, dose-escalation, multicenter phase I/II clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy. The secondary endpoints of this study were to evaluated the efficacy HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy.